Teva intros generic Sandostatin LAR Depot
Teva is introducing the only generic version of Novartis AG's Sandostatin LAR Depot, in the United States.
Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome.
“With today’s launch of octreotide acetate for injectable suspension (the generic version of Sandostatin LAR Depot), Teva is providing patients a new option for this important treatment,” said Ernie Richardsen, senior vice president of U.S. commercial generics.” He continued, “This first-to-market launch showcases Teva’s expertise in bringing complex generic formulations to market and demonstrates once again our ability to not only sustain a generics powerhouse, but also to bring value to patients and healthcare systems.”
Read more: Teva rolls out generic Nexavar tablets]
Sandostatin LAR Depot had a market value of $826 million as of July 2024, per IQVIA.
Octreotide acetate for injectable suspension is used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for:
- Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal.
- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
[Read more: Teva obtains FDA nod for generic Forteo]
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.